Introduction: Antipsychotics are widely used and often in combination with other drugs, thereby frequently subjected to drug-drug interactions. This review will provide a summary of potential pharmacokinetic (PK) and pharmacodynamic (PD) drug interactions associated with antipsychotic drugs.
Introduction
Antipsychotics are widely used in patients who suffer from schizophrenia, bipolar disorder, and other psychiatric illnesses, often long term as these conditions are chronic, treatment resistant, or lifelong. As a disease worsens, antipsychotics are often used in combination with other psychotropic medications. 1 Thus, the likelihood of drug interactions increases and may result in complex and unpredictable outcomes. Clinicians should have a good understanding of these drug interactions to maximize the therapeutic benefit and minimize side effects. The aim of this article is to review significant pharmacokinetic (PK) and pharmacodynamic (PD) interactions with antipsychotics.
Pharmacokinetic Interactions of Antipsychotics
The potential combination or removal of other drugs may affect the way an antipsychotic or its metabolites are handled in the body, resulting in changes to the antipsychotic or its active by-products by altering its absorption, distribution, metabolism, or excretion. 1 From a clinical perspective, these PK interactions help explain or predict bioavailability, onset, duration of activity, and interactions between drugs that alter their metabolism and excretion. 2 It is beyond the scope of this article to review every PK interaction reported. Thus, the focus will be limited to drug-drug interactions with oral antipsychotics that may have a substantial influence in the clinical setting. 3 Most FGAs are highly protein bound (85%-90%), and although changes in protein binding can have an influence on individual PK parameters, those changes caused by drug-drug interactions will usually not influence the clinical exposure of a patient, and no routine adjustments in dosing regimen are necessary. 3, 4 Oral formulations undergo extensive liver metabolic transformations including glucuronidation, oxidation, reduction, and methylation. Most FGAs are metabolized by the cytochrome P450 (CYP) system, and most common PK drug-drug interactions involve effects on metabolism via the CYP system as listed in Table 1 . Because of the many active metabolites and biological variability, there exist differences of the clinical response among FGAs and significant difficulty in predicting those interactions most likely to cause harm if not detected. The elimination halflives of FGAs vary from 18 to 40 hours, and steady-state levels of oral drugs are reached in approximately 3 to 8 days. Numerous factors such as genetically determined metabolic rates, age, and co-administration of other hepatically metabolized drugs affect the half-life to such a degree that plasma levels may vary among individuals by 10-to 20-fold. The major routes of excretion are through urine and feces by way of bile, with minor pathways of excretion via sweat, saliva, tears, and breast milk.
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Pharmacokinetic Interactions With Second-Generation Antipsychotics
Most PK interactions with second-generation antipsychotics (SGAs) arise at the stage of drug metabolism and usually involve changes to drug-metabolizing enzymes when other psychotropic agents or medications in the treatment of concomitant medical illness are added. 12 A summary of PK drug interactions related to metabolism is presented in Table 2 . In addition to drug-drug interactions related to the metabolism of SGA discussed in Table 2 , it is important to take into consideration PK interactions consisting of changes in the absorption, distribution, or elimination of the antipsychotic that may result after the addition of another chemical agent.
In theory, studies of PK interactions conducted during the drug-development stage in a controlled environment in animal models, and thereafter in healthy volunteers using population PK modeling, are unambiguous; however, in reality, it is prudent to keep in mind that the interactions may be multifactorial. For example, formulation and drugmolecule differences, food-dependent absorption, lipophilicity resulting in high volume of distributions, and competition for protein binding leading to subsequent displacement interactions interfere with PK. In addition, the state of the hepatic portal system and a patient's genetic variability, which in turn may affect the drug's hepatic and renal clearance, play important roles, resulting in clinically significant drug interactions. 1 
Pharmacodynamic Interactions
Pharmacodynamic drug-drug interactions occur when drugs being added to the antipsychotic compete at the receptor level, interfering with the therapeutic efficacy or perhaps contributing to an adverse effect. For example, when levodopa, a drug used for Parkinsonism with agonistic action at dopamine D 2 receptor is added, the antipsychotic through its dopamine antagonism can oppose the effects of levodopa. The result may culminate in worsening motor function, a relapse of psychosis or a combination thereof. Table 3 lists several examples of PD interactions resulting in antagonistic, additive, or synergistic effects most often leading to adverse effects but, at times, rarely and deliberately augmented to obtain a favorable effect.
Discussion
Nondrug patient factors (such as age, sex, concomitant diseases, genetic polymorphisms, caffeine and drug intake Direct glucuronidation by UGT1A4 and oxidative metabolism by CYP1A2.
Fluvoxamine increases plasma concentration of asenapine by 29%. Should be co-administered with caution, while observing for adverse effects such as drowsiness, dizziness, and increased appetite. Asenapine (CYP2D6 inhibitor) increases paroxetine levels 2-fold. Clozapine Oral: tablet, orally disintegrating tablet
Extensive first-pass in the liver and gut; predominantly metabolized by CYP1A2, 2D6. Also, contributed by CYP3A4 to active norclozapine.
Caffeine and clozapine are both metabolized by CYP1A2, and caffeine at 400 to 1000 mg may competitively inhibit clozapine metabolism with significant increase (26%) in clozapine levels. Fluoxetine, possibly by CYP2D6 inhibition increases clozapine and norclozapine levels. It is suggested that measuring clozapine levels may be useful. Fluvoxamine inhibition of CYP1A2 leads to a significant increase in clozapine levels. Paroxetine significantly increases plasma clozapine and norclozapine levels and may expose to clozapine toxicity. Sertraline may produce significant increases in plasma clozapine levels-the risk of clozapine toxicity should be considered. Phenytoin may reduce serum concentrations of clozapine via CYP1A2 induction. Cimetidine may increase clozapine levels by 50%.
Ranitidine is a safer alternative. Digoxin and warfarin are highly protein-bound drugs. Dose should be monitored and adjusted as necessary. Carbamazepine, a strong inducer of both CYP3A4 and P-gp, decreased the AUC by 37%. In vitro studies have shown that paliperidone is a P-gp substrate. Paroxetine, a potent CYP2D6 inhibitor, increased paliperidone on average 16%, but the clinical relevance is unknown. Divalproex sodium ER formulation increased C max and AUC by 50%; manufacturer recommends a dose reduction of paliperidone after clinical assessment. Quetiapine Oral: tablet, extended release tablet
Primarily hepatic metabolism via CYP3A4 to active N-desalkyl quetiapine and 2 inactive metabolites. Metabolism reduced by ;30% with advancing age.
Carbamazepine, phenytoin, rifampin, and St John's wort will increase quetiapine clearance. Up to a 5-fold increase of the original quetiapine dose is advised by the manufacturer if used in combination long term (.7-14 days); also advised is to reduce quetiapine dose accordingly upon discontinuation of strong CYP3A4 inducers. CYP3A4 inhibitors such as ritonavir, erythromycin, ketoconazole, and nefazodone may increase quetiapine levels. The manufacturer advises a reduction in the quetiapine dose to one sixth if used concomitantly. Risperidone Oral: tablet, disintegrating tablet, solution
Extensive metabolism via CYP3A4 and CYP2D6 to 9-hydroxyrisperidone (active); Ndealkylation as a minor pathway.
Risperidone dose should be increased and titrated up to double the patient's usual dose when adding to carbamazepine and other inducers. The initial dose of risperidone should be reduced (max ¼ 8 mg per day) with CYP2D6 inhibitors such as fluoxetine and paroxetine. habits, and use of herbal medications) as well as drugrelated factors (such as formulation, dose, and route of administration) contributing to antipsychotic drug interactions are beyond the scope of this review; nevertheless, these factors should be taken into consideration when assessing PK-and PD-drug interactions comprehensively. Some studies find proposed PK principles lacking a significant impact on the plasma levels of the antipsychotic, suggesting that theoretical drug interactions may not always occur as anticipated. In addition, researchers suggest that multiple CYP enzyme involvement in an antipsychotic metabolism will make it more difficult to predict the extent of the drug interaction because at low doses one type of CYP metabolism may predominate, while at higher doses another CYP enzyme interaction may possibly be prominent. 1 During this review, it is also noted that newer antipsychotics introduced in recent years have morespecific, standardized PK information and recommendations in their product labeling compared with those agents marketed decades ago. However, there is little information on monitoring of plasma concentration levels to gauge the response of a drug interaction. The blood-brain distribution of the antipsychotic drugs or their potentially active metabolites may or may not contribute to varying plasma concentrations among individuals, suggesting that plasma levels may not be a useful measure in evaluating PK and PD interactions. Moreover, the time course of the drug interactions are rarely mentioned in literature, but clinicians should take into consideration the timeline (eg, half-life, time for steady state) when evaluating potential PK and PD interactions especially in patients on multiple and longterm drug treatment. Lastly, avoidance of unnecessary polypharmacy, knowledge of drug-interaction profiles, experience, and good clinical judgement are essential in preventing significant and potentially adverse PK-and PD-drug interactions in patients receiving antipsychotics.
